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Abstract
Background. Haematopoietic stem cells (HSC) have been
shown to migrate to the ischemic kidney. The factors that
regulate the trafficking of HSC to the ischemic damaged
kidney are not fully understood. The stromal cell-derived
factor-1 (SDF-1)/CXCR4-axis has been identified as the
central signalling axis regulating trafficking of HSC to
the bone marrow. Therefore, we hypothesized that SDF-
1/CXCR4 interactions are implicated in the migration of
HSC to the injured kidney.
Methods.HSCwereisolatedfrommousebonemarrowand
labelledwithacelltracker.Acceptormiceweresubjectedto
unilateralischemiaandreceivedHSCintravenouslydirectly
afterreperfusion.Inaddition,inseparategroupsofacceptor
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mice, endogenous SDF-1 or HSC-associated CXCR4 was
blocked or kidneys were injected with SDF-1.
Results. Exogenous HSC could be detected in the tubules
and interstitium of the kidney 24 h after ischemic injury.
Importantly, the amount of HSC in the ischemic kidney
was markedly higher compared to the contralateral kid-
ney. Neutralizing endogenous SDF-1 or HSC-associated
CXCR4 did not prevent the migration of HSC. No increase
in the number of labelled HSC could be observed after
local administration of SDF-1, as was also determined in
bilateral kidney ischemia.
Conclusion.Inconclusion,systemicallyadministeredHSC
preferentially migrate to the ischemic injured kidney. This
migration could not be prevented by blocking the SDF-
1/CXCR4-axis or increased after local administration of
SDF-1.
Keywords: HSC migration; ischemia/reperfusion; kidney;
SDF-1/CXCR4-axis
Introduction
Acute renal failure (ARF) is a major clinical problem that
affects up to 5% of hospitalized patients and has a mor-
tality rate of 50–80% in these hospitalized patients [1].
Ischemia/reperfusion (I/R) injury is the major initiator of
ARF and is caused by a sudden transient drop in blood flow
to the kidney frequently occurring in shock, sepsis and dur-
ing renal transplantation. I/R injury leads to a cascade of
events affecting mainly tubular epithelial cells (TEC) in the
corticomedullary region of the kidney, resulting in struc-
tural alterations including loss of brush border and cell
polarity, and necrosis and apoptosis of damaged TEC [2].
Depending on the severity of injury, renal tubules have the
capacitytoregenerateandeventuallyrestorethetubulewith
normal epithelium resulting in functional recovery of the
kidney.
Haematopoietic stem cells (HSC) are suggested to be
involved in this regenerative process. Several studies have
found Y-chromosome-positive TEC in renal female grafts
transplanted into male recipients, and in kidneys of female
mice transplanted with male bone marrow [3–5]. However,
thiswasarareevent,occurringonlyinasmallpercentageof
tubules. Although initial reports showed a high number of
bone marrow-derived cells (BMC) with an epithelial phe-
notype after renal I/R injury [6,7], carefully designed ex-
periments by the same and other groups could only observe
a few epithelial-like BMC in renal tubules after ischemic
injury [8–10]. Since the levels of BMC that engraft the
injured tubules and develop into functional TEC are very
low,theircontributiontorenalrepairisthoughttobeminor.
Enhancing the migration of HSC to the injured kidney may
result in a significant contribution of these HSC to renal
repair, and hence has therapeutic potential.
The mechanisms that regulate the trafficking of HSC to
the ischemic damaged kidney, however, remain unclear. A
better understanding of the factors that regulate the migra-
tionofHSCintotheinjuredkidneyisessentialforthedevel-
opment of strategies to improve HSC kidney engraftment
and repair. The chemokine stromal cell-derived factor-1
(SDF-1, also known as CXCL12) and its receptor CXCR4
have been identified as the central signalling axis regulat-
ing the trafficking of HSC. In immune-deficient mice, the
SDF-1/CXCR4-axis is essential for efficient homing of hu-
man stem cells as indicated by the impaired repopulation
of the bone marrow after blocking stem cell-associated
CXCR4 [11–13]. In addition, local administration of re-
combinant SDF-1 results in an increased homing of stem
cells to the liver, spleen and bone marrow [11,12].
SDF-1isupregulatedafterinjuryindiverseexperimental
models including skin ischemia [14], toxic liver injury
[11], myocardial infarct [15,16] and DNA damage [17].
We (unpublished data) and others [18] have shown that in
the kidney, after I/R injury SDF-1 protein levels are upreg-
ulated. T¨ ogel et al. also observed a selective homing of ex-
ogenousadministeredBMCtotheinjuredkidneyandcould
inhibit this by blocking bone marrow-associated CXCR4
[18]. Taken together, current literature suggests a role
for the SDF-1/CXCR4-axis in HSC migration to injured
organs.
In the present study, we thoroughly characterized the
involvement of the SDF-1/CXCR4-axis in the migration of
HSC to the injured kidney.
Subjects and methods
Mice
Eight-week-old male C57Bl/6 (B6) mice were purchased from Charles
River (Maastricht, The Netherlands) and housed under specific pathogen-
free conditions receiving food and water ad libitum. All experimental
procedures were approved by the local Animal Care and Use Committee
of the University of Amsterdam, The Netherlands.
Isolation of HSC
Total bone marrow was collected from male B6 mice by flushing fe-
murs and tibiae. Erythrocytes were lysed in 160 mM NH4Cl, 10 mM
KHCO3 and 0.1 mM EDTA (pH 7.4, 0.22 µm filtered). Cells were la-
belled with an APC-conjugated monoclonal antibody to c-Kit (BD Bio-
sciences, Alphen a/d Rijn, The Netherlands) for 20 min, washed with
FACS buffer (0.5% BSA, 0.35 mM EDTA in PBS), and the population of
cells expressing high levelsof c-Kit (c-Kithigh) was collected using a FAC-
SAria cell sorter (Becton Dickinson, Breda, The Netherlands). The sorted
c-Kithigh population was labelled with the fluorescent cell tracker CM-DiI
(Invitrogen, Breda, The Netherlands) according to the manufacturer’s pro-
tocol. Unlike other membrane stains, this dye binds covalently to cellular
thiols and therefore is well retained in cells throughout fixation steps.
After washing, the cells were resuspended in sterile saline. For CXCR4
neutralization, 106 c-Kithigh BMC were pre-incubated with 20 µg anti-
murine CXCR4 neutralizing mAb (R&D, Abingdon, UK) for 30 min at
37◦C [11].
Analysis of the expression of lineage markers, Sca-1 and CXCR4 on
the sorted c-Kithigh BMC was performed by incubating the cells with a
cocktail of rat-anti-mouse lineage markers (Ter119, CD45R, Ly6, CD8a,
CD4, CD11b, all from BD Biosciences) for 30 min followed by a FITC-
conjugated polyclonal antibody to rat-IgGs (Dako, Heverlee, Belgium)
and a PE-conjugated monoclonal antibody to Sca-1 (BD Bioscience) for
30 min, or by incubating with an FITC-conjugated monoclonal antibody
to CXCR4 (BD Bioscience) for 30 min. Analyses were performed on
an FACSCalibur (Becton Dickinson) and showed that after cell sorting
the c-Kithigh BMC expressed no lineage markers, as previously reported
[19], and that at least 85% of the c-Kithigh population expressed Sca-1.
Therefore,thepopulationofcellsusedinthisstudyishighlyenrichedwith
c-Kit+, Sca-1+ and Lin− cells, which are considered to represent HSC
[20] and will hereafter be referred to as HSC. After cell sorting, 90% of
our HSC population expressed CXCR4, the receptor for SDF-1.2084 I. Stroo et al.
In vitro migration assay
In vitro migration assays were performed in triplicate with 5 µm pore
size transwells (Corning Life Sciences, Schiphol-Rijk, The Netherlands)
coated with 0.5 µg/mL VCAM-1 (R&D) in PBS. To the lower com-
partment, medium (DMEM; Gibco, Invitrogen cell culture, Breda, The
Netherlands) supplemented with 200 ng/mL recombinant murine SDF-1α
(recSDF-1; PeproTech EC, London, UK) or medium alone was added.
To the upper compartment, 0.1 × 106 CM-DiI-labelled HSC were ap-
plied and allowed to migrate for 2 h at 37◦C. The neutralizing ca-
pacity of anti-SDF-1 was determined by adding 17 µg/mL neutraliz-
ing anti-human/mouse SDF-1α (anti-SDF-1, R&D) to the medium with
recSDF-1 in the lower compartment. The neutralizing capacity of anti-
CXCR4 was determined by adding HSC pre-incubated with CXCR4
(20 µg/106 HSC) to the upper compartment. The amount of migrated
CM-DiI-labelled HSC was determined on an FACSCalibur (Becton
Dickinson) and expressed as a percentage of the input.
In vivo migration assay
B6 mice received 0.6 × 106 CM-DiI-labelled HSC, or CM-DiI-labelled
HSCpre-incubatedwithaCXCR4blockingantibody(anti-CXCR4group;
20 µg/106 HSC) [11] or CM-DiI-labelled HSC mixed with free anti-
SDF-1 (anti-SDF-1 group; 2 mg/kg) [21] intravenously. Mice were killed
24 h after injection, and bone marrow aspirates were analysed by flow
cytometry for the presence of injected HSC.
Renal I/R injury model
Unilateral renal I/R injury was induced by clamping the left renal artery
for 55 min under general anaesthesia [0.1 mg/10 g mouse of fentanyl
citrate fluanisone midazolam mixture, containing 1.25 mg/ml midazolam
(Roche, Mijdrecht, The Netherlands), 0.08 mg/ml fentanyl-citrate, and
2.5 mg/ml fluanisone (Vetapharma, Leeds, UK)]. The contralateral (right)
kidney was used as internal control. In the recSDF-1-treated group, mice
received an intrarenal injection of 2 µg( 2 5µg/mL) recSDF-1 in a 0.2%
peptide hydrogel (PuraMatrix; BD Biosciences) in both the ischemic and
contralateral kidney. Bilateral renal I/R injury was induced by clamping
both renal arteries for 45 min under general anaesthesia, immediately
followed by an intrarenal injection of 2 × 1 µg recSDF-1/0.2% hydro-
gel in the left kidney. The right kidney (control) was injected with the
same volume of vehicle. After surgery, mice received intravenously 0.6 ×
106 CM-DiI-labelled HSC, or CM-DiI-labelled HSC pre-incubated with a
CXCR4 blocking antibody (anti-CXCR4 group, 20 µg/106 HSC) [11] or
CM-DiI-labelled HSC mixed with free anti-SDF-1 antibody (anti-SDF-1
group;2mg/kg,R&D)[21]inatotalvolumeof200µL.Foranalgesicpur-
poses, mice received subcutaneously 50 µg/kg buprenorphin (Temgesic;
Schering-Plough, Brussels, Belgium) after closing the abdomen and were
killed 24 h after surgery. Kidneys were harvested, and blood samples were
obtained via heart puncture and transferred to heparin tubes.
Detection of fluorescent-labelled HSC in the kidney
Formalin-fixedkidneyswereembeddedinparaffin.Fourmicrometrethick
serial sections were cut, and every 10th section was used for examination.
The sections were deparaffinized in fresh ethanol gradient series and sub-
sequently embedded in the Vectashield HardSet mounting medium with
DAPI (Vector Laboratories, Amsterdam, The Netherlands). The presence
of injected HSC was examined by fluorescence microscopy using a Leica
CTR5000(LeicaMicrosystems,Rijswijk,TheNetherlands)equippedwith
the Nuance multispectral imaging system (Cambridge Research, Woburn,
MA, USA).
Kidney sections stored in a cold medium were used for flow cytometric
analysis. The kidneys were minced through a 70 µm gauze, and a single
cell suspension was made. Erythrocytes were lysed in 160 mM NH4Cl,
10 mM KHCO3 and 0.1 mM EDTA (pH 7.4). After washing, the kid-
ney cells were analysed on a FACSCalibur (Becton Dickinson). For back-
groundcorrection,ischemicandcontralateralkidneysofmicenotinjected
with CM-DiI-labelled HSC were used.
Statistical analyses
Resultsareexpressedasmean±standarderrorofthemean(SEM),unless
mentioned otherwise. Data were analysed using a non-parametric Mann–
Whitney U-test. The values of P ≤ 0.05 were considered statistically
significant.
Fig.1. HSCpreferentiallymigratetotheischemicinjuredkidney,andthis
migrationisnotalteredbymanipulatingtheSDF-1/CXCR4-axis.Oneday
after unilateral ischemia for 55 min and subsequent intravenous adminis-
tration of CM-DiI-labelled HSC, kidneys were harvested and analysed by
flow cytometry for the presence of exogenous HSC (i.e. CM-DiI and c-Kit
positive). Flow cytometry plots of (A) a contralateral and (B)a ni s c h e m i c
kidneydemonstrateahigherpercentageofexogenousHSCintheischemic
kidney.(C)ExogenousHSCincontralateral()andischemic()kidneys
of mice with I/R injury and intravenously HSC (control) and of mice with
additional neutralization of endogenous SDF-1 (anti-SDF-1), neutraliza-
tion of HSC-associated CXCR4 (anti-CXCR4) and intrarenal recSDF-1
(recSDF-1), showed an increase in exogenous HSC in the ischemic kidney
compared to the contralateral. However, this was only significant in the
control and recSDF-1 mice (both ∗P = 0.03). Anti-SDF-1 or anti-CXCR4
treatment did not result in a decreased migration of HSC towards the is-
chemickidney.IntrarenalrecSDF-1didnotincreasethemigrationofHSC
towards the ischemic or contralateral kidney. Background fluorescence of
ischemic and contralateral kidneys without HSC administration was sub-
tracted to correct for autofluorescence of (dead) cells. Data are expressed
as mean ± SEM, n = 4.
Results
HSC preferentially migrate to ischemic damaged kidney
To study the migration of HSC towards the injured kidney,
mice were subjected to unilateral I/R injury, after which
they received 0.6 × 106 CM-DiI-labelled HSC into the tail
vein. Twenty-four hours later, there was a significant (P =
0.03) increase in HSC migrating to the ischemic injured
kidney compared to the contralateral kidney as assessed
by flow cytometric analysis (Figure 1). The background
fluorescence of ischemic and contralateral kidneys without
HSC administration was subtracted to correct for autofluo-
rescence of (dead) cells.
To localize the exogenous HSC in the injured kidney, we
visualized the presence of these cells in renal tissue. Spec-
tral imaging was used to make a clear distinction between
the exogenous HSC and endogenous kidney and inflam-
matory cells by reducing the autofluorescent background,
thereby reducing possible false positive hits (Figure 2ASDF-1/CXCR4-axis in HSC migration to the kidney 2085
Fig. 2. Exogenous HSC migrate to tubules and the interstitium. Fluorescent detection with TX2 filter of intravenously administered CM-DiI-labelled
HSC in the injured kidney one day after I/R. (A and B) High magnification (40×) of the renal corticomedullary region. Two bright fluorescent cells are
present in/close to injured tubules. (B) Spectral imaging was used to reduce the autofluorescent signal of the kidney, showing that the bright fluorescent
cells are not endogenous kidney or inflammatory cells. (E)O v e r l a yo ft h e( C) TX2-filter image with (D) DAPI staining image corresponding to the
boxed area in (A). Arrows point to the two bright exogenous cells; a clear overlay is seen with the DAPI staining.
and B). Of interest, exogenous HSC were mainly detected
inthe corticomedullary area, the part of the kidney most af-
fected by I/R injury. More specifically, we found that these
cells were localized in dilated tubules, in close proximity to
dilated tubules and in the interstitium (Figure 2).
SDF-1 and CXCR4-neutralizing antibodies inhibit HSC
migration in vitro and in vivo
To prove the efficacy of recSDF-1 as well as the neutraliz-
ing antibodies against SDF-1 and CXCR4, in vitro migra-
tion assays were performed. As depicted in Figure 3A, the
medium supplemented with recSDF-1 resulted in an 8-fold
increase of HSC migration compared to the medium alone.
Adding anti-SDF-1 to the assay or pre-incubating the HSC
with anti-CXCR4 resulted in reduced migration of HSC
cells by 65 and 40%, respectively.
To validate whether anti-SDF-1 and anti-CXCR4 were
also able to inhibit the migration of HSC in vivo,H S C
were injected into the tail vein of naive mice with or with-
out blocking either endogenous SDF-1 or HSC-associated
CXCR4 with a monoclonal antibody as previously de-
scribed [11,13,18,21]. Under physiological conditions, the
bone marrow is the niche for HSC; the basal level of hy-
poxia in the bone marrow microenvironment may explain
the constitutive and regional expression of SDF-1 in the
bone marrow and the CXCR4-dependent stem and progen-
itorcelltropismtothebonemarrow[22].Twenty-fourhours
afteradministration,wecoulddetectCM-DiI-labelledHSC
inthebonemarrow(Figure3C).Subtractionofbackground
signal from non-injected animals (Figure 3B) revealed that
0.21%±0.01%oftotalbonemarrowconsistedofCM-DiI-
labelled HSC that had migrated towards the bone marrow.
However, after neutralizing SDF-1 (Figure 3D) or CXCR4
(Figure 3E), no CM-DiI-labelled HSC could be detected in
the bone marrow indicating that we have established a reli-
able in vivo system to disrupt the SDF-1/CXCR4-mediated
migration of HSC.
Migration of HSC is not prevented by blocking the
SDF-1/CXCR4-axis
In order to investigate the involvement of the SDF-1/
CXCR4-axis in the migration of HSC to the injured kid-
ney, we utilized two independent approaches to inhibit
SDF-1/CXCR4 function. Unexpectedly, neutralization of
endogenous SDF-1 or HSC-associated CXCR4 did not
result in a significantly decreased migration of exoge-
nous HSC to the ischemic injured or contralateral kidney
(Figure 1C). In contrast, in both groups, there was an in-
crease in exogenous HSC in the ischemic kidney com-
pared to the contralateral kidney, although this was not
significant.
HSC migration is not influenced by exogenous SDF-1
in vivo
In contrast to other studies [11,13,18,21], we were un-
able to significantly influence the migration of HSC to the
ischemic injured kidney by blocking the SDF-1/CXCR4-
axis. Therefore, we hypothesized that endogenous SDF-1
levels in ischemic kidneys may be insufficient to prop-
erly attract HSC. To test this hypothesis, both contralateral2086 I. Stroo et al.
Fig. 3. Neutralizing SDF-1 and CXCR4 antibodies inhibit migration of
HSC towards recSDF-1 and the bone marrow. (A)I na nin vitro migration
assay, the amount of migrated CM-DiI-labelled HSC from the upper to the
lower compartment was determined as a percentage of the input. After 2 h
at 37◦C, 1.4% passive (control) migration of HSC was observed. Addition
of200ng/mLrecSDF-1tothemediuminthelowercompartmentincreased
HSC migration 8-fold. Neutralizing SDF-1 in the lower compartment or
neutralizing HSC-associated CXCR4 in the upper compartment resulted
in a 65% and 40% reduction of recSDF-1-induced migration, respectively.
All experiments were performed in triplicate, bars represent mean ± SD,
n = 2. (B–E)I na nin vivo migration assay, the percentage of exogenous
HSC (i.e. c-kit and CM-DiI positive) in the bone marrow was determined
byflowcytometry24hafterintravenousinjection.Flowcytometryplotsof
(B) a non-injected control, (C) a positive control, (D) anti-CXCR4-treated
mice and (E) anti-SDF-1-treated mice reveals only exogenous HSC in the
positive control; no exogenous HSC could be detected in the bone marrow
of anti-CXCR4- or anti-SDF-1-treated mice.
and I/R injured kidneys received recSDF-1 (at a double
dose as described before [11,12]). Twenty-four hours af-
ter intrarenal injection of recSDF-1, there was still a 4.3×
(P < 0.01) increase in renal SDF-1 as compared with vehi-
cle injected kidney. In accordance with the previous experi-
ments,significantly(P=0.03)moreHSCmigratedtowards
the ischemic injured kidney compared to the contralateral
kidney (Figure 1C). However, we could not observe an in-
creased migration of the HSC towards the ischemic or con-
tralateral kidneys locally injected with recSDF-1 compared
to the control group.
Fig. 4. HSC migration is not influenced by locally administered SDF-
1. One day after bilateral ischemia and local administration of saline or
recSDF-1 followed by intravenous injection of CM-DiI-labelled HSC, no
difference was observed in migration of the exogenous HSC. Flow cy-
tometry plots of (A) a saline and (B) a recSDF-1-treated ischemic kidney.
(C) Graphical representation of the mean (± SEM) percentage of exoge-
nous HSC in the saline (control) and recSDF-1-treated ischemic kidneys
shows no difference between the groups. Data are expressed as mean ±
SEM, n = 4.
Subsequently, we hypothesized that a more severe and
systemic type of danger might be necessary. Therefore,
bilateral I/R injury was induced and directly after reperfu-
sion local injections of recSDF-1 in the left and saline in
therightkidneywereperformed.Immediatelyaftersurgery,
mice received HSC into the tail vein and 24 h later the
kidneys were analysed. Again, we could not observe any
effect of the locally injected recSDF-1 on the migration
of HSC since both kidneys were engrafted with the same
amount of exogenous administered HSC (Figure 4).
Discussion
The aim of our study was to establish the importance of
the SDF-1/CXCR4-axis in the migration of HSC to the
ischemic injured kidney, in order to eventually manipulate
this axis for therapeutic purposes. The contribution of HSC
in post-ischemic renal tissue repair is controversial. First of
all, the capacity of HSC to engraft tubules after ischemic
injuryismuchlowerthanoriginallyreported.Initialstudies
in chimeric mice stated that 21% [6] or even 80% [7] of the
tubules contained BMC. However, some of these numbers
are thought to be overestimated due to false-positive results
as a consequence of β-gal leaking by the BMC [23]. Sex-
mismatched and GFP-chimeric mice studies published in
2005showedonlyafewBMCinthetubulesafterI/Rinjury
[8,10], whereas Duffield and colleagues could not observe
any BMC in post-ischemic tubules [24,25]. Secondly, theSDF-1/CXCR4-axis in HSC migration to the kidney 2087
biological significance of HSC in repair after I/R injury is
challenged,sincelownumbersofBMCinthetubulesdonot
makeasignificantcontributiontorenalfunctionalrecovery
[8,10]. Therefore, mechanisms to increase the migration of
HSC may result in a significant contribution of these cells
to tubular repair and hence have therapeutic potential.
To determine whether the SDF-1/CXCR4-axis is the
driving force for the recruitment of HSC to the injured
kidney, we followed the migration of exogenous HSC in a
unilateral renal I/R model. This model gives the opportu-
nitytocomparethemigrationofHSCininjuredandnormal
tissue within one mouse, in contrast to experimental mod-
els such as cisplatin-induced renal injury and bilateral renal
I/R injury. Here, we demonstrate that HSC migrate to the
injured kidney and are even able to migrate into damaged
tubules. In line with our data, Lin et al. [7] and T¨ ogel et al.
[18] have shown that the homing process of BMC is se-
lective for the ischemic injured kidney. Our study, how-
ever, extends these findings as we have studied migration
of purified HSC instead of whole bone marrow that is a
heterogeneous population of cells consisting, amongst oth-
ers, of inflammatory cells, mesenchymal stem cells and
onlyasmallpercentageofHSC.Surprisingly,manipulating
the SDF-1/CXCR4-axis in three different and independent
manners did not result in a significantly altered migration
of exogenous HSC.
Previous studies have shown the importance of the
SDF-1/CXCR4-axis in the migration of BMC. This was
done either by blocking endogenous SDF-1, blocking
BMC-associated CXCR4 or increasing locally SDF-1
[11,12,18,21,26]. Our results are at variance with the cur-
rent opinion that SDF-1 is the mediator of HSC trafficking
to injured organs. The neutralizing antibodies were cho-
sen based on their proven functionality in previous studies.
Neutralization with the same function-blocking anti-SDF-
1 monoclonal antibody and dose as used in the present
study significantly attenuated HSC accumulation within
thegrowingplatelet-richthrombusinanarterialthrombosis
mouse model [21]. In order to neutralize HSC-associated
CXCR4, the same protocol was used as reported previ-
ously to be effective in blocking the recruitment of BMC
[18] or HSC [11,13,18]. In addition, our in vitro and
in vivo HSC migration assays demonstrated a decreased
migration towards high recSDF-1 levels and bone marrow,
respectively, after neutralizing SDF-1 or CXCR4. There-
fore, we believe that our experimental set-up is highly re-
liable to study the role of this axis. Despite this, we could
not observe a significant effect of neutralizing SDF-1 or
its receptor CXCR4 on the migration of HSC to the injured
kidney.Sincetheseresultsdonotsupportthecurrentreports
on SDF-1-involvement in HSC-migration, we conducted a
third independent experiment to determine the effect of lo-
cal SDF-1 administration on the migration of exogenous
HSC. Despite the previously reported preferred migration
of HSC towards high SDF-1 gradient in liver, bone marrow
and spleen [11,12], we could not observe this in both the
unilateral and bilateral renal I/R injury model. However, in
accordance with our results, it has been reported that BMC
migration to the lung could not be influenced significantly
by manipulating the SDF-1/CXCR4-axis in both a non-
injured [12] and a bleomycine-injured [27] mouse model.
This indicates that other mechanisms may be involved in
HSC migration to the kidney and lung.
We also did not find an effect of the local administra-
tion of recSDF-1 in the non-injured (contralateral) kidney
on renal engraftment of HSC compared to the non-treated
contralateral kidney. These results suggest that injury is
necessary for HSC migration and that SDF-1 alone is not
sufficientformigration.Thiswasalsoobservedintheheart,
whereoverexpressionofSDF-1withoutinjurycouldnotin-
duce the homing of BMC [16]. In addition, the results from
the bilateral I/R model, where both the SDF-1 and saline-
injected kidney had the same percentage of migration, in-
dicate that the exogenous administered HSC cells did not
migrate preferentially towards high SDF-1 gradient.
OurresultsindicatethatI/Rinjuryinducesthehomingof
HSC in the injured kidney and that this preferred migration
is not exclusively dependent on the SDF-1/CXCR4-axis.
Homing of HSC towards the ischemic damaged kidney
could be much more complex. Several other factors are
described to be involved in stem cell migration and in ad-
dition are known to be induced after I/R injury. These fac-
tors include the chemokine GROβ [28], the glycosamino-
glycan hyaluronic acid [29], the nuclear factor HMGB1
[30] and the growth factor HGF [11]. Interestingly, in
a recently published report, a flexible hierarchy of hom-
ing molecules was proposed, providing an explanation for
some of the contradictory findings in the literature [31].
Herein, the authors show that in a mouse model of HSC
transplantation, SDF-1 was not required for stem cell hom-
ing due to compensatory action via the VLA-4/VCAM-1
interaction [31].
In conclusion, our initial hypothesis that SDF-1/CXCR4
interactions are implicated in the migration of HSC to the
injured kidney is not supported by the results in this report.
In sharp contrast to studies in other injured organs, our
results indicate that migration of HSC to the ischemic dam-
aged kidney is not solely dependent on the SDF-1/CXCR4
signalling axis.
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